ArticleCureus2026
Immunohistochemical Expression of Vimentin in Breast Carcinoma and Its Correlation With Histopathological Prognostic Factors.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVimentin is a mesenchymal intermediate filament protein and an important marker of epithelial-mesenchymal transition, which has been implicated in tumor invasion, progression, and aggressive biological behavior in breast carcinoma. Its expression in invasive breast carcinoma may correlate with established pathological prognostic factors and thereby provide additional prognostic information.
objectiveTo evaluate the expression of vimentin in invasive breast carcinoma of female patients and to determine its correlation with markers associated with adverse histopathological features. METHODOLOGY: This retrospective observational study was carried out in the Department of Pathology, Gandhi Medical College, Bhopal, Madhya Pradesh, India. A total of 70 cases of invasive ductal carcinoma of the breast, not otherwise specified (IDC-NOS), were included. Histopathological evaluation was performed on hematoxylin and eosin-stained sections, and tumor grading was done according to the Modified Bloom-Richardson grading system. Tumor size and lymph node status were categorized according to standard pathological criteria. Immunohistochemical staining for vimentin was performed on representative paraffin-embedded tissue sections. Vimentin expression was assessed as positive or negative based on cytoplasmic staining in invasive tumor cells.
resultsVimentin expression was observed in 17 of 70 cases (24.28%). An increasing trend of vimentin positivity was seen with increasing tumor size, with positivity in 0 of 3 cases (0.0%) in tumors measuring ≤2 cm, 5 of 28 cases (17.85%) in tumors measuring >2 to ≤5 cm, and 12 of 39 cases (30.76%) in tumors measuring >5 cm. Vimentin positivity also increased with nodal involvement and was seen in 4 of 32 node-negative tumors (12.50%), 3 of 17 N1 tumors (17.64%), 8 of 18 N2 tumors (44.44%), and 2 of 3 N3 tumors (66.66%), although the association was not statistically significant (p = 0.06). A strong association was observed with histological grade: none of the Grade I tumors [0 of 19 cases (0.0%)] were positive, whereas positivity was present in 7 of 38 Grade II tumors (18.42%) and 10 of 13 Grade III tumors (76.92%).
conclusionsVimentin expression in invasive breast carcinoma is associated with adverse pathological features, particularly larger tumor size, higher nodal burden, and most strongly, higher histological grade. Its marked expression in poorly differentiated tumors suggests that vimentin may serve as a useful adjunct prognostic marker of aggressive tumor biology in invasive breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.